Should You Buy Tcr2 Therapeutics Inc (TCRR) Stock Tuesday Morning?

Tuesday, March 07, 2023 06:48 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Tcr2 Therapeutics Inc (TCRR) Stock Tuesday Morning?

Tcr2 Therapeutics Inc (TCRR) is down Tuesday morning, with the stock decreasing -3.09% in pre-market trading to 1.57. TCRR's short-term technical score of 51 indicates that the stock has traded more bullishly over the last month than 51% of stocks on the market. In the Biotechnology industry, which ranks 117 out of 146 industries, Tcr2 Therapeutics Inc ranks higher than 65% of stocks. Tcr2 Therapeutics Inc has risen 12.50% over the past month, closing at $1.38 on February 7. During this period of time, the stock fell as low as $1.10 and as high as $1.78. TCRR has an average analyst recommendation of Strong Buy. The company has an average price target of $8.14.

TCRR has an Overall Score of 59. Find out what this means to you and get the rest of the rankings on TCRR!

See Full TCRR Report

Tcr2 Therapeutics Inc has a Long-Term Technical rank of 33. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 67% of the market scoring higher. In the Biotechnology industry which is number 129 by this metric, TCRR ranks better than 129% of stocks.

Important Dates for Investors in TCRR:

-Tcr2 Therapeutics Inc is set to release earnings on 3/28/2023. Over the last 12 months, the company has reported EPS of $-3.09. -We do not have a set dividend date for Tcr2 Therapeutics Inc at this time. Click Here To Get The Full Report on Tcr2 Therapeutics Inc (TCRR)